LEIDEN, the Netherlands, May 23, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the appointment of Dr.
… NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR), a biopharmaceutical company dedicated to changing lives through … In addition, ProQR has granted the underwriters a 30-day option to purchase up to 862,500 additional ordinary shares … for the offering. Kempen & Co is acting as the Company’s European financial advisor in relation to this offering. A …
… retinal disease, into the clinic and continuing the development of our portfolio of transformative RNA medicines … ProQR. “QR-421a has shown promising activity in both the optic cup and zebra fish models and we are excited about the … gene and will be conducted at expert sites in the US and Europe. It will be a double-masked, randomized study …